Literature DB >> 6295671

Interaction of Epstein-Barr virus with leukaemic B cells in vitro. I. Abortive infection and rare cell line establishment from chronic lymphocytic leukaemic cells.

A B Rickinson, S Finerty, M A Epstein.   

Abstract

Leukaemia B cell populations, each with an individual pattern of monoclonal surface immunoglobulin expression, were obtained from 23 patients with chronic lymphocytic leukaemia (CLL) and, following exposure to a potent dose of Epstein-Barr (EB) virus in vitro, were monitored for expression of the virus associated nuclear antigen EBNA, for activation of immunoglobulin synthesis and for virus-induced transformation to an established cell line. Although possessing the EB virus receptor, CLL cells were generally refractory (vis-à-vis normal adult B cells) to the full effects of the viral infection. All the leukaemic populations tested developed a small proportion of EBNA positive cells within a few days post-infection, but in most instances this disappeared with no subsequent evidence of viral activity. In certain cases, however, the EBNA staining became more intense, involving a larger fraction of the population and persisting for some weeks, but again this was not accompanied by virus-induced immunoglobulin synthesis or transformation. In contrast, the leukaemic cells from a single patient, tested on three separate occasions, regularly responded to EB virus infection with the rapid establishment of an EBNA positive B cell line in which the restricted pattern of surface and cytoplasmic immunoglobulin expression (gamma lambda) exactly matched that present on the original leukaemic cells.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6295671      PMCID: PMC1536694     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  21 in total

1.  Efficiency of transformation of lymphocytes by Epstein-Barr virus.

Authors:  E Henderson; G Miller; J Robinson; L Heston
Journal:  Virology       Date:  1977-01       Impact factor: 3.616

2.  Identification of the target cells in human B lymphocytes for transformation by Epstein-Barr virus.

Authors:  T Katsuki; Y Hinuma; N Yamamoto; T Abo; K Kumagai
Journal:  Virology       Date:  1977-12       Impact factor: 3.616

Review 3.  Chronic lymphocytic leukaemia as an immunoproliferative disorder.

Authors:  J C Brouet; M Seligmann
Journal:  Clin Haematol       Date:  1977-02

4.  Lymphocyte subpopulations in chronic lymphocytic leukemia. Characterization by cell surface markers, cytotoxic activity, and mitogenic stimulation.

Authors:  H Mellstedt; D Pettersson
Journal:  Scand J Immunol       Date:  1974       Impact factor: 3.487

5.  Assay of the infectivity of Epstein-Barr virus by transformation of human leucocytes in vitro.

Authors:  D J Moss; J H Pope
Journal:  J Gen Virol       Date:  1972-11       Impact factor: 3.891

6.  Cytogenetic studies on human lymphoblastoid cell lines from Burkitt's lymphomas and other sources.

Authors:  J E Jarvis; G Ball; A B Rickison; M A Epstein
Journal:  Int J Cancer       Date:  1974-12-15       Impact factor: 7.396

7.  Surface markers on human B and T lymphocytes. VIII. Association between complement and Epstein-Barr virus receptors on human lymphoid cells.

Authors:  M Jondal; G Klein; M B Oldstone; V Bokish; E Yefenof
Journal:  Scand J Immunol       Date:  1976       Impact factor: 3.487

8.  Herpes-type virus and chromosome marker in normal leukocytes after growth with irradiated Burkitt cells.

Authors:  W Henle; V Diehl; G Kohn; H Zur Hausen; G Henle
Journal:  Science       Date:  1967-09-01       Impact factor: 47.728

9.  A quantitative analysis of the susceptibility of human leukocytes to transformation by Epstein-Barr virus.

Authors:  T Katsuki; Y Hinuma
Journal:  Int J Cancer       Date:  1976-07-15       Impact factor: 7.396

10.  Surface markers on human B and T lymphocytes. II. Presence of Epstein-Barr virus receptors on B lymphocytes.

Authors:  M Jondal; G Klein
Journal:  J Exp Med       Date:  1973-12-01       Impact factor: 14.307

View more
  11 in total

1.  The establishment of cell lines from chronic B cell leukaemias: evidence of leukaemic origin by karyotypic abnormalities and Ig gene rearrangement.

Authors:  J V Melo; L Foroni; V Brito-Babapulle; L Luzzatto; D Catovsky
Journal:  Clin Exp Immunol       Date:  1988-07       Impact factor: 4.330

2.  Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation.

Authors:  Lapo Alinari; Kiran V Mahasenan; Fengting Yan; Vrajesh Karkhanis; Ji-Hyun Chung; Emily M Smith; Carl Quinion; Porsha L Smith; Lisa Kim; John T Patton; Rosa Lapalombella; Bo Yu; Yun Wu; Satavisha Roy; Alessandra De Leo; Stefano Pileri; Claudio Agostinelli; Leona Ayers; James E Bradner; Selina Chen-Kiang; Olivier Elemento; Tasneem Motiwala; Sarmila Majumder; John C Byrd; Samson Jacob; Said Sif; Chenglong Li; Robert A Baiocchi
Journal:  Blood       Date:  2015-03-05       Impact factor: 22.113

3.  Mitogenic stimulation of malignant B cells. Chronic lymphocytic leukaemia: secretion of monoclonal IgM by in vitro-induced plasmablasts.

Authors:  A C Bloem; C O van Hooff; E J Bast; R E Ballieux
Journal:  Clin Exp Immunol       Date:  1984-03       Impact factor: 4.330

4.  Establishment and characterization of a new Epstein-Barr virus transformed cell line from a human B cell lymphoma.

Authors:  O Janssen; B Heinze; C R Bartram; M Pawlita; T Binder; H Heimpel; K Diehl; D Kabelitz
Journal:  Blut       Date:  1990-03

5.  Inhibition of Epstein-Barr-virus-transformed human chronic lymphocytic leukaemic B cells with monoclonal-antibody-adriamycin (doxorubicin) conjugates.

Authors:  Z Zhu; J Kralovec; T Ghose; M Mammen
Journal:  Cancer Immunol Immunother       Date:  1995-04       Impact factor: 6.968

6.  In vitro activation of leukaemic B cells by interleukin-4 and antibodies to CD40.

Authors:  D H Crawford; D Catovsky
Journal:  Immunology       Date:  1993-09       Impact factor: 7.397

7.  Evidence for the involvement of B lymphoid cells in polycythemia vera and essential thrombocythemia.

Authors:  W H Raskind; R Jacobson; S Murphy; J W Adamson; P J Fialkow
Journal:  J Clin Invest       Date:  1985-04       Impact factor: 14.808

Review 8.  New aspects on the pathogenesis, diagnostic procedures, and therapeutic management of chronic lymphocytic leukemia.

Authors:  C M Wendtner; B Schmitt; M Bergmann; T Röhnisch; R Buhmann; M Hallek
Journal:  Int J Hematol       Date:  2001-01       Impact factor: 2.319

9.  Establishment and Characterization of PCL12, a Novel CD5+ Chronic Lymphocytic Leukaemia Cell Line.

Authors:  Andreas Agathangelidis; Lydia Scarfò; Federica Barbaglio; Benedetta Apollonio; Maria Teresa Sabrina Bertilaccio; Pamela Ranghetti; Maurilio Ponzoni; Gabriella Leone; Valeria De Pascali; Lorenza Pecciarini; Paolo Ghia; Federico Caligaris-Cappio; Cristina Scielzo
Journal:  PLoS One       Date:  2015-06-25       Impact factor: 3.240

10.  EBV genome carrying B lymphocytes that express the nuclear protein EBNA-2 but not LMP-1: Type IIb latency.

Authors:  Eva Klein; Noémi Nagy; Abu Eahsan Rasul
Journal:  Oncoimmunology       Date:  2013-02-01       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.